← All trials
NCT00533949
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2007
- Primary completion
- Jun 1, 2013
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 544
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Radiation Therapy Oncology GroupLead sponsor
- Mayo ClinicStudy chair
- University of Texas at HoustonStudy chair
- Cornell UniversityStudy chair
- University of WisconsinStudy chair
- State University of New York, SyracuseStudy chair
- University of AlabamaStudy chair
- Wake Forest UniversityStudy chair
- University of North Carolina at Chapel HillStudy chair
- University of South FloridaStudy chair
- Thomas Jefferson UniversityStudy chair
- National Cancer Institute (NCI)Collaborator
- North Central Cancer Treatment GroupCollaborator
- NRG OncologyCollaborator
- Washington University in St. LouisOverall official - principal investigator
- Henry Ford Health SystemStudy chair
- State University of New York, BuffaloStudy chair
- Cancer and Leukemia Group B (CALGB)Collaborator
- The University of Texas, DallasStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.